Post-SSRI Sexual Dysfunction

Post-SSRI Sexual Dysfunction (PSSD) is a controversial condition that has been discussed in recent years. It is the term given to persistent sexual side effects after stopping or reducing the use of Selective Serotonin Reuptake Inhibitors (SSRIs) medications. SSRIs are mostly prescribed for the treatment of mental health disorders such as depression, anxiety, and obsessive-compulsive disorder. However, they can also indirectly affect menstrual cycles and sexuality. PSSD can lead to symptoms such as loss of libido, erectile dysfunction, anorgasmia, and decreased genital sensation. It is important to note that not all individuals who use SSRIs experience PSSD, and it is not fully understood why some people develop the condition while others do not. While the prevalence of PSSD is difficult to determine due to a lack of sufficient data, some studies have estimated that it may affect up to 70% of people who have taken SSRI medications. However, due to the fragmented nature of the data, the exact scope is still ambiguous. There are currently no standardized treatments for PSSD. Some individuals report success with therapies such as cognitive-behavioral therapy, pelvic floor muscle exercises or the use of medications that increase sexual function. However, those treatments are not provided by FDA-approved drugs to treat PSSD. It is essential for both patients and healthcare providers to be aware of the potential risks of SSRIs and the possibility of PSSD. It is critical to have an accurate understanding of the factors that contribute to the development of the condition, the available treatment options, and the impact on the quality of life of those affected.